[go: up one dir, main page]

MX2011012232A - Formas de dosificacion liquidas de isotretinoina. - Google Patents

Formas de dosificacion liquidas de isotretinoina.

Info

Publication number
MX2011012232A
MX2011012232A MX2011012232A MX2011012232A MX2011012232A MX 2011012232 A MX2011012232 A MX 2011012232A MX 2011012232 A MX2011012232 A MX 2011012232A MX 2011012232 A MX2011012232 A MX 2011012232A MX 2011012232 A MX2011012232 A MX 2011012232A
Authority
MX
Mexico
Prior art keywords
isotretinoin
dosage forms
liquid dosage
present
relates
Prior art date
Application number
MX2011012232A
Other languages
English (en)
Inventor
Sanjay Kumar Motwani
Shashikanth P Isloor
Vinod Arora
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of MX2011012232A publication Critical patent/MX2011012232A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona a una solución farmacéutica que comprende isotretinoína o sales de la misma. La presente invención además se relaciona a los procesos para preparar tales composiciones.
MX2011012232A 2009-05-20 2010-05-20 Formas de dosificacion liquidas de isotretinoina. MX2011012232A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1039DE2009 2009-05-20
PCT/IB2010/052254 WO2010134047A2 (en) 2009-05-20 2010-05-20 Liquid dosage forms of isotretinoin

Publications (1)

Publication Number Publication Date
MX2011012232A true MX2011012232A (es) 2012-04-10

Family

ID=54261167

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012232A MX2011012232A (es) 2009-05-20 2010-05-20 Formas de dosificacion liquidas de isotretinoina.

Country Status (8)

Country Link
US (2) US20120259013A1 (es)
EP (1) EP2432553A2 (es)
CN (1) CN102802729A (es)
BR (1) BRPI1010970A2 (es)
CA (1) CA2762391C (es)
MX (1) MX2011012232A (es)
SG (2) SG2014011969A (es)
WO (1) WO2010134047A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435427B2 (en) 2000-09-22 2008-10-14 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
US9244235B2 (en) 2008-10-17 2016-01-26 Foro Energy, Inc. Systems and assemblies for transferring high power laser energy through a rotating junction
US9138786B2 (en) * 2008-10-17 2015-09-22 Foro Energy, Inc. High power laser pipeline tool and methods of use
SG176097A1 (en) 2009-05-20 2011-12-29 Ranbaxy Lab Ltd Topical retinoid solutions
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
CA2889711A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
MX2016015465A (es) 2014-05-29 2017-03-27 Sun Pharmaceutical Ind Ltd Composicion farmaceutica oral de isotretinoina.
JP2017516794A (ja) * 2014-06-02 2017-06-22 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． 経口イソトレチノイン医薬組成物
CA2952771A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
BR112017001963A2 (pt) 2014-07-31 2017-11-21 Sun Pharmaceutical Ind Ltd composição farmacêutica oral, seu processo de preparação e método de tratamento
US9750711B2 (en) * 2014-10-01 2017-09-05 Sun Pharmaceutical Industries Limited Low dose oral pharmaceutical composition of isotretinoin
US20190046484A1 (en) * 2015-02-12 2019-02-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
MX390018B (es) * 2015-10-30 2025-03-20 Leo Pharma As Formulaciones de isotretinoina y usos y metodos de las mismas.
US10973790B2 (en) 2015-10-30 2021-04-13 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
US10945981B2 (en) 2019-05-17 2021-03-16 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
EP4236915A4 (en) * 2020-11-01 2024-10-23 Idrs Labs Pvt Ltd ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF ISOTRETINOIN
JP2025534534A (ja) 2022-07-01 2025-10-16 アクロテック バイオファーマ インコーポレーティド イソトレチノインを含む医薬組成物、その調製のためのプロセス及びその使用
CN119033671B (zh) * 2024-09-05 2025-04-04 中南大学湘雅三医院 一种异维a酸油剂及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322438A (en) 1979-08-06 1982-03-30 United States Of America Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne
CA1282326C (en) 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
PE20001227A1 (es) 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
US6339107B1 (en) * 2000-08-02 2002-01-15 Syntex (U.S.A.) Llc Methods for treatment of Emphysema using 13-cis retinoic acid
US7435427B2 (en) 2000-09-22 2008-10-14 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
US20060241078A1 (en) * 2005-03-16 2006-10-26 Ahmed Salah U Pharmaceutical compositions comprising a contraceptive agent in solution and a teratogen
CN101346128B (zh) * 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法

Also Published As

Publication number Publication date
BRPI1010970A2 (pt) 2019-04-09
US20170165217A1 (en) 2017-06-15
CA2762391C (en) 2017-02-07
US20120259013A1 (en) 2012-10-11
EP2432553A2 (en) 2012-03-28
CN102802729A (zh) 2012-11-28
SG176096A1 (en) 2011-12-29
SG2014011969A (en) 2014-09-26
CA2762391A1 (en) 2010-11-25
WO2010134047A3 (en) 2011-11-24
WO2010134047A2 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
MX2011012232A (es) Formas de dosificacion liquidas de isotretinoina.
ZA201206254B (en) Novel salts for the manufacture of pharmaceutical compositions
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
MY170713A (en) Treatment protocol of diabetes type 2
NZ608116A (en) Triazine-oxadiazoles
EA201270216A1 (ru) Фармацевтический состав
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
EA201300388A1 (ru) Соединения замещенного бензамида
MY184303A (en) Notch pathway signaling inhibitor compound
EA029539B8 (ru) Фармацевтическая композиция ситаглиптина
IN2012DN02139A (es)
PH12013502204A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
MX362879B (es) Usos novedosos.
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
MX344473B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
PL2901857T3 (pl) Sposób wytwarzania 3-chloro-4,5,6-trifluoro-pikolinonitrylu
MX2012001411A (es) Proceso para la preparacion de derivados de acido 1-(2-halobifenil-4-il)-ciclopropanocarboxilico.
MX2013000009A (es) Procedimiento de preparacion de la sal de l-arginina de perindoprilo.
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
EP2828236A4 (en) METHOD FOR PRODUCING BIOZIDER AQUEOUS COMPOSITIONS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal